SYRS Syros: Net Sales Margin

syros.com (SYRS) - corporate logo

The primary driver for Syros Pharmaceuticals (SYRS) is its gene management platform for cancer therapy, which generates cash flow through patent agreements. The net operating margin illustrates this trend, where 0.00 characterizes this valuation parameter. Future prospects depend on the results of oncology trials, while potential demand is driven by the shortage of effective treatments for complex leukemias.

syros.com (SYRS) - Net Margin from 07/04/2022 to 03/29/2025

Syros - analytical breakdowns and key metrics (SYRS)

- share price and expert price forecast:
Analysis of all company metrics:Syros Pharmaceuticals Inc. - SYRS
Finished products of Syros Pharmaceuticals Inc.

For Syros Pharmaceuticals (SYRS), which develops targeted leukemia therapy based on genomic analysis, sales margins determine the financial stability of the innovation cycle. This metric is calculated as the ratio of net income to total revenue, measuring the portion of profit derived from every dollar of revenue. The trend in net income per unit of revenue reflects the efficiency of R&D cost management. It is critical for investors to track this trend to assess operating leverage. An increase in this indicator signals a transition from cost-intensive development to the commercial monetization of the drug.

Main competitors

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Net Sales Margin|Net Return on Sales IMNN (Imunon, Inc.)|Net Sales Margin PHIO|MBIO - Net Margin|Net Sales Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Net Margin|Applied DNA - Net Sales Margin|Net Margin Bluebird Bio|ImmunoPrecise (IPA) - Net Margin|Net Profit Margin OMGA (Omega)|Net Margin Singular Genomics Systems|Net Margin regulusrx.com RGLS|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX